Impact of Fibrotic Metabolic Dysfunction-Associated Steatohepatitis as a New Indication on Semaglutide Eligibility in the US Adult Population. - van Kleef LA; Michel M; Savas M; Pustjens J; Theel W; van Rossum EFC; Paik JM; Younossi ZM; Janssen HLA; Labenz C; Schattenberg JM; Brouwer WP (Gastro hep advances, 2026)